Atopic Dermatitis: Background, Objectives and Future Perspectives (Superresponders).

Abstract

In this Special Issue entitled Atopic Dermatitis: New Perspectives, we have tried to collect research of special interest related mainly to the incorporation of pathophysiological aspects and therapeutic novelties in this regard. Pereyra et al. [1] carry out a systematic review and network meta-analysis (NMA) in which they perform a short-term evaluation of the efficacy and safety of biological molecules and small molecules that have recently been incorporated into our therapeutic arsenal. Upadacitinib and Abrocitinib are the drugs with the highest efficacy, both in monotherapy and in association with topical corticosteroids (TCS); however, they were also associated with the highest risk of adverse effects, while monoclonal antibodies demonstrated a better safety profile. Atopic dermatitis (AD) has scarcely studied comorbidities, one of which is its impact on the function and sexual health of patients. Linares-Gonzalez et al. [2] establish that, unlike other psychological comorbidities such as anxiety and depression, sexual dysfunction is a scarcely explored field in the literature. This dysfunction is mainly focused on men in large population studies and clinical diagnoses, without being explored through specific and validated questionnaires. Is there any infectious compromise that can worsen the clinical patterns of AD? Navarro-Triviño et al. [3] present a study on sensitization to Malassezia furfur in patients with head and neck AD. It is important to understand the differential diagnosis and approach this correctly, as sensitization to Malassezia furfur may be one of the main causes of worsening symptoms, especially in patients being treated with dupilumab.